Maxwell Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Maxwell Biosciences's estimated annual revenue is currently $3.4M per year.
- Maxwell Biosciences's estimated revenue per employee is $155,000
Employee Data
- Maxwell Biosciences has 22 Employees.
- Maxwell Biosciences grew their employee count by -8% last year.
Maxwell Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP R&D Strategy | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Director Investor Relations | Reveal Email/Phone |
4 | Sr. Director Operations | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Chief Scientific Officer, Co-inventor | Reveal Email/Phone |
7 | Sr. Director Drug Development | Reveal Email/Phone |
8 | Chairman | Reveal Email/Phone |
9 | Chairman | Reveal Email/Phone |
10 | Operations Associate | Reveal Email/Phone |
Maxwell Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Maxwell Biosciences?
A New Virucide Drug By Mimicking Natural Human Antiviral Proteins Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This world-first drug class called Maxwell's PeptoidsTM mimics natural human immune system antimicrobial peptides. Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against Herpes virus and SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target†virucidal drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics. Maxwell is raising funds for advanced preclinical and human trials.
keywords:N/A
N/A
Total Funding
22
Number of Employees
$3.4M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Maxwell Biosciences News
MaxWell Biosciences: Edward Rudnic was named COO of Texas-based Maxwell. Rudnic was the founder, chairman, and CEO of MiddleBrook...
After leading MiddleBrook Pharmaceuticals onto Wall Street, Edward Rudnic, Ph.D. is joining Maxwell Biosciences as chief operating officer.
Maxwell Biosciences Announces the Appointment of Edward Rudnic, Ph.D., as Chief Operating Officer. Published: Apr 21, 2022. April 21, 2022 12:00 UTC.
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.1M | 22 | -8% | N/A |
#2 | $2M | 22 | N/A | N/A |
#3 | $2.2M | 22 | N/A | N/A |
#4 | $3.2M | 22 | N/A | N/A |
#5 | $7.5M | 22 | 5% | N/A |